secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001551152-23-000004
Event type: earnings
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie expects Q4 2022 $243M acquired IPR&D charge, cutting adjusted EPS by $0.14
--------------------------------------------------------------------------------

- Q4 2022 acquired IPR&D and milestones expense of $243M pre-tax; $0.14 hit to GAAP and adjusted EPS.
- Q4 2022 adjusted EPS guidance revised to $3.51-$3.55 from prior $3.65-$3.69.
- Full-year 2022 adjusted EPS guidance revised to $13.70-$13.74 from prior $13.84-$13.88.
- Results are preliminary and subject to financial statement closing procedures.
- AbbVie does not forecast acquired IPR&D expense due to transaction uncertainty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000004/0001551152-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000004/abbv-20230106.htm
  HTML page:      https://secwatch.observer/filing/0001551152-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer